Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Resolver to Immunex

NEW YORK, Feb 26 - Rosetta Inpharmatics has licensed its Rosetta Resolver Expression Data Analysis System to Immunex, Rosetta said Monday.

The Resolver is a bioinformatics platform that analyzes gene expression. It can be used with a variety of microarrays from different manufacturers. including Affymetrix GeneChips and Agilent DNA arrays. Rosetta released the latest version of the system last quarter, and has granted Agilent Technologies sole distribution rights to it. 

"This order of the Rosetta Resolver system by a biopharmaceutical company of the caliber of Immunex is further evidence of the strength of the Rosetta Resolver gene expression system for the analysis of the genetic causes of disease in combination with DNA microarrays," Stephen Friend, Rosetta's CEO, said in a statement. "We are very pleased to add Immunex Corporation to our growing list of excellent customers." 

The parties did not disclose the financial terms of this agreement.

Since launching the Resolver, Rosetta has licensed it to the Harvard Center for Genomic Reasearch, Paradigm Genetics, and GlaxoSmithKline. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.  
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.